Do you have COPD or want to help us understand COPD? If so, you may be able to take part in a research study. We want to learn more about how nose inflammation is related to COPD. We are looking for people with COPD and healthy volunteers for this study. Compensation provided.

Are you a healthy person? Have you wanted to get involved in clinical research in lung diseases? If so, you can join our registry list of interested individuals through a quick online form. We will give you a call if there are studies that you may be eligible for.

Do you have COPD and repeated breathing flares ending up in the hospital? If you are under the care of a doctor at UNC, you may be eligible for a research study to find out which of two medicines, roflumilast or azithromycin, can help your COPD control.

Researchers are looking for current and former smokers with or without COPD to enroll in a registry to be contacted for future studies.

To collect research samples from CF patients already having a clinically indicated colonoscopy. We're collecting a few additional samples on top of what is collected for clinical purposes to give to researchers for future projects. This will increase your time of procedure around 5 minutes.

To 1) measure and improve the quality of care, 2) determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches, 3) understand risk factors for outcomes , and 4) facilitate funded clinical trials of new therapies and collaboration within the pulmonary arterial hypertension (PAH) community.

Evaluate the regional lung function and structural changes using MRI in children with cystic fibrosis (CF) prescribed either immediate or tailored therapy for their pulmonary exacerbation. The primary outcome measure for this ancillary study is the change in ventilation defect percentage (VDP) calculated from Xe MRI, which represents the fraction of the lung with absent or reduced ventilation.

This is a 24-week Phase 2, double-blind study testing the safety of PF-07868489 in patients with Pulmonary Arterial Hypertension (PAH). The primary objective is to evaluate PF-07868489 vs placebo in patients with PAH. The study will evaluate the occurrence of adverse events, change in baseline vital signs and laboratory values, as well as changes in baseline electrocardiogram (ECG) characteristics

Evaluate the differences between two different treatment durations for exacerbations in a pediatric sample to determine which should be clinical standard.

We are performing a clinical study to determine the optimal frequency for medications for infected pleural fluid, referred to as intrapleural enzyme therapy (IET). Participants will either receive once daily IET or twice daily IET. We hypothesize that once daily IET will be non-inferior to twice daily IET.